Kenvue
KVUE
$19.24
-0.36%
Kenvue Inc. is the world's largest pure-play consumer health company, generating over $15 billion in annual revenue from iconic brands like Tylenol, Listerine, Aveeno, and Neutrogena across categories such as self-care, essential health, and skin health. Spun off from Johnson & Johnson in May 2023, Kenvue holds a dominant market position as a pure-play consumer health leader with unparalleled brand recognition and scale. The current investor narrative is dominated by the pending acquisition by Kimberly-Clark, announced in November 2025 and expected to close in the second half of 2026, which has created a floor on the stock price but also introduced uncertainty around deal completion and regulatory approvals. Additionally, the company is navigating post-IPO challenges including margin recovery, litigation overhang, and the need to demonstrate organic growth acceleration.…
KVUE
Kenvue
$19.24
Related headlines
KVUE 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Kenvue's 12-month outlook, with a consensus price target around $19.83 and implied upside of +3.1% versus the current price.
Average Target
$19.83
0 analysts
Implied Upside
+3.1%
vs. current price
Analyst Count
—
covering this stock
Price Range
$18 - $23
Analyst target range
Kenvue is covered by 12 analysts, with a consensus recommendation of 'Hold' (mean rating of 2.79 on a 1-5 scale where 1 is Strong Buy). The average price target is $19.83, implying just 2.9% upside from the current price of $19.28. The distribution leans neutral, with no strong bullish or bearish tilt—recent actions from Citigroup, Barclays, and UBS have maintained Neutral/Equal Weight ratings, while Jefferies downgraded from Buy to Hold in January 2026. The target range spans from a low of $18.00 to a high of $23.00. The low target of $18.00 implies 6.6% downside and likely reflects risks such as deal failure, litigation costs, or margin compression. The high target of $23.00 implies 19.3% upside and assumes successful closing of the Kimberly-Clark acquisition, operational improvements, and multiple expansion. The spread between low and high ($5.00, or 26% of the average) indicates moderate uncertainty, typical for a stock undergoing a major M&A event. The lack of recent upgrades or downgrades suggests analysts are in a wait-and-see mode pending deal closure, and the Hold consensus reflects the balanced risk/reward at current levels.
Drowning in data?
Find the real signal!
Bulls vs Bears: KVUE Investment Factors
Kenvue presents a balanced risk/reward profile, with the bull case anchored by the pending acquisition at a premium, improving margins, and an attractive forward valuation. The bear case centers on limited upside to analyst targets, acquisition uncertainty, and modest organic growth. Currently, the bull side has slightly stronger evidence given the margin improvement and low forward P/E, but the stock's fate hinges on the successful closure of the Kimberly-Clark deal. The single most important tension is whether the acquisition completes: if it does, the stock could approach the $23 high target; if it fails, downside to $18 or below is plausible. Until deal clarity emerges, the stock is likely to trade in a narrow range near the average target.
Bullish
- Pending Acquisition by Kimberly-Clark: The acquisition at a premium provides a floor for the stock price, with the deal expected to close in H2 2026. The high analyst target of $23.00 implies 19.3% upside from the current $19.28, reflecting deal optimism.
- Improving Profitability and Margins: Q1 2026 net margin expanded to 12.1% from 8.6% a year ago, and operating margin rose to 21.9% from 14.9%. This demonstrates successful cost efficiencies and mix improvement, driving EPS growth of 47% YoY to $0.25.
- Attractive Forward Valuation: Forward P/E of 15.6x represents a 29% discount to the industry average of ~22x, and the PEG ratio of 0.52x suggests undervaluation relative to expected earnings growth of ~20% in fiscal 2026.
- Strong Free Cash Flow Generation: Trailing free cash flow of $1.823 billion provides a FCF yield of ~5.5%, which is attractive for a consumer staples company. This cash flow supports the $398 million quarterly dividend and provides financial flexibility.
Bearish
- Limited Upside to Average Target: The average analyst price target of $19.83 implies only 2.9% upside from the current price of $19.28. The consensus rating is 'Hold' (2.79 on a 1-5 scale), indicating analysts see balanced risk/reward with no strong conviction.
- Acquisition Uncertainty and Regulatory Risk: The Kimberly-Clark acquisition, announced in November 2025, faces regulatory approvals and could be blocked or delayed. If the deal falls through, the stock could fall to the low analyst target of $18.00 (6.6% downside) or lower.
- High Payout Ratio and Dividend Sustainability: The payout ratio is 107.5%, meaning dividends exceed earnings. While FCF covers the dividend, the high payout ratio leaves little room for error and could pressure the dividend if earnings falter.
- Modest Revenue Growth Trajectory: Q1 2026 revenue growth of 4.5% YoY, while accelerating, remains in the mid-single digits. This is below high-growth peers and limits the potential for multiple expansion without a significant catalyst.
KVUE Technical Analysis
Kenvue is in a recovery uptrend, with the stock up 10.2% over the past three months and 8.3% over six months, though it remains 14.3% lower over the past year. The current price of $19.28 sits at 60% of its 52-week range ($14.02–$22.87), indicating it has recovered from its lows but still has room to run before challenging resistance. This positioning suggests the stock is in a rebuilding phase, with momentum building but not yet overextended. Short-term momentum is accelerating: the 1-month price change of +2.6% and 3-month change of +10.2% both outpace the S&P 500's respective gains of 0.8% and 3.5%, showing strong relative strength. The 1-month relative strength of +1.77 confirms Kenvue is outperforming the market in the near term, while the 1-year relative strength of -30.8% highlights the longer-term underperformance from which it is recovering. This divergence between short-term strength and long-term weakness suggests a potential trend reversal is underway, supported by the stock's ability to hold above its 50-day moving average since late June. Key support lies at the 52-week low of $14.02, while resistance is at the 52-week high of $22.87. A breakout above $22.87 would signal a resumption of the post-IPO uptrend and could target the $25 area, while a breakdown below $14.02 would negate the recovery and suggest further downside. With a beta of 0.44, Kenvue is significantly less volatile than the broader market, meaning it offers downside protection in selloffs but may lag during sharp market rallies—a key consideration for risk-adjusted positioning.
Beta
0.44
0.44x market volatility
Max Drawdown
-38.2%
Largest decline past year
52-Week Range
$14-$22
Price range past year
Annual Return
-10.3%
Cumulative gain past year
| Period | KVUE Return | S&P 500 |
|---|---|---|
| 1m | -0.5% | +0.2% |
| 3m | +10.4% | +3.7% |
| 6m | +10.6% | +8.0% |
| 1y | -10.3% | +18.2% |
| ytd | +11.1% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
KVUE Fundamental Analysis
Kenvue's revenue trajectory is steadily growing, with Q1 2026 revenue of $3.909 billion representing 4.5% year-over-year growth, accelerating from the 3.0% growth in Q4 2025 and 2.9% in Q1 2025. The trailing twelve-month revenue stands at approximately $15.3 billion, with the Self Care segment ($1.699B in Q1) being the largest driver, followed by Essential Health ($1.151B) and Skin Health & Beauty ($1.059B). The consistent mid-single-digit growth reflects stable demand for consumer health staples, though the pace remains modest relative to high-growth peers. Profitability is solid and improving: Q1 2026 net income was $474 million, up from $322 million in Q1 2025, with net margin expanding to 12.1% from 8.6% a year ago. Gross margin improved to 58.9% from 58.0% in the prior year quarter, while operating margin rose to 21.9% from 14.9%, driven by cost efficiencies and favorable mix. The company is consistently profitable with EPS of $0.25 in Q1 2026, up from $0.17 in Q1 2025, and the trailing PE of 22.3x reflects reasonable earnings power. Kenvue maintains a healthy balance sheet with a debt-to-equity ratio of 0.79 and generated $1.823 billion in trailing free cash flow, providing ample coverage for its $398 million quarterly dividend (payout ratio ~84%). The current ratio of 0.96 is slightly below 1.0, indicating tight liquidity, but operating cash flow of $489 million in Q1 comfortably covers capex of $139 million. ROE of 13.7% and ROA of 7.1% demonstrate efficient capital allocation, though the FCF yield of ~5.5% (based on market cap of $33B) is attractive for a consumer staples name.
Quarterly Revenue
$3.9B
2026-03
Revenue YoY Growth
+4.5%
YoY Comparison
Gross Margin
58.9%
Latest Quarter
Free Cash Flow
$1.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is KVUE Overvalued?
Since Kenvue has positive net income, the primary valuation metric is the P/E ratio. The trailing P/E of 22.3x is elevated relative to the forward P/E of 15.6x, implying the market expects significant earnings growth over the next year—consistent with the consensus EPS estimate of $1.41 for fiscal 2026, which would represent 20% growth from the trailing twelve-month EPS of $1.17. This gap between trailing and forward multiples suggests the market is pricing in a recovery in profitability. Compared to the household & personal products industry average P/E of approximately 22x (based on sector data), Kenvue's trailing P/E of 22.3x is essentially in line, but its forward P/E of 15.6x represents a 29% discount to the industry forward average of ~22x, implying the market is not fully crediting the expected earnings rebound. The PEG ratio of 0.52x (based on forward earnings growth) suggests the stock is undervalued relative to its growth rate, as a PEG below 1.0 typically indicates value. Historically, Kenvue's trailing P/E has ranged from a low of 17.2x (Q1 2026) to a high of 148x (Q2 2024, when earnings were depressed). The current 22.3x is near the lower end of its historical band, suggesting the stock is not expensive by its own standards. However, the P/E was as high as 35x in early 2025, so the compression reflects the market's adjustment to normalized earnings. The price-to-sales ratio of 2.18x is below the industry average of ~3.0x, further supporting a value-oriented assessment.
PE
22.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 17x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Kenvue's debt-to-equity ratio of 0.79 is manageable, but the current ratio of 0.96 indicates tight liquidity, meaning the company relies on operating cash flow to meet short-term obligations. The payout ratio of 107.5% is concerning as dividends exceed net income, though free cash flow of $1.823 billion provides coverage. Margin pressure from input costs or competitive pricing could erode the recent improvements in gross margin (58.9%) and operating margin (21.9%). Revenue concentration in the Self Care segment (43% of Q1 revenue) exposes the company to shifts in consumer health trends or regulatory changes in OTC medications.
Market & Competitive Risks: The stock's beta of 0.44 reduces market correlation but also means it may lag during strong rallies. Valuation compression risk is moderate given the trailing P/E of 22.3x is in line with the industry, but the forward P/E of 15.6x already discounts significant earnings growth. Competitive threats from larger players like Procter & Gamble and Reckitt Benckiser could pressure market share. Regulatory risks include potential FTC challenges to the Kimberly-Clark acquisition, which could delay or block the deal. Recent news highlights analyst downgrades and technical overbought conditions, suggesting near-term caution.
Worst-Case Scenario: If the Kimberly-Clark acquisition fails due to regulatory opposition or financing issues, the stock could fall to the 52-week low of $14.02, representing a 27.3% decline from the current price of $19.28. Additionally, a litigation setback or a sharp deterioration in margins could push the stock below the low analyst target of $18.00. In a severe recession, consumer health spending could dip, and the stock might test its historical max drawdown of -38.2%, implying a potential loss of over 38% from current levels. The realistic downside in a deal-failure scenario is approximately -27% to the 52-week low.
